Vaccinovigilance in Europe - Need for timeliness, standardization and resource

Bulletin of the World Health Organization

Volumn 82, Issue 11, 2004, Pages 828-835

  Lankinen, Kari S ^a   Pastila, Satu ^a   Kilpi, Terhi ^b   Nohynek, Hanna ^b   Mäkelä, P Helena ^b   Olin, Patrick ^c  

^a PSR Consulting Ltd   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

Adverse drug reaction reporting systems organization and administration; Databases, Factual standards; International cooperation; Legislation, Drug; Product surveillance, Postmarketing organization and administration; Vaccines adverse effects

Indexed keywords

VACCINE;

IMMUNIZATION;

COMPARATIVE STUDY; DATA BASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPE; EUROPEAN UNION; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; IMMUNIZATION; NORWAY; PRACTICE GUIDELINE; QUESTIONNAIRE; REVIEW; STANDARDIZATION; SWITZERLAND; VACCINATION REACTION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATABASES, FACTUAL; EUROPE; EUROPEAN UNION; HEALTH CARE SURVEYS; HUMANS; IMMUNIZATION PROGRAMS; NATIONAL HEALTH PROGRAMS; NORWAY; PRODUCT SURVEILLANCE, POSTMARKETING; PUBLIC HEALTH INFORMATICS; QUESTIONNAIRES; SWITZERLAND; TIME FACTORS; VACCINES;

EID: 9644307980     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. The World Bank. World development report 1993. New York: Oxford University Press; 1993.
2. Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998;351:637-41.
3. Ascherio A, Zhang S, Hernan M, Olek M, Coplan P, Brodovicz K. [Hepatitis B vaccination and the risk of multiple sclerosis: case-control studies]. Gastroentérologie Clinique et Biologique 2001;25:927-9. In French.
4. Pless R, Duclos P. Reinforcing surveillance for vaccine-associated adverse events: the Advisory Committee on Causality Assessment. Canadian Journal of Infectious Diseases 1996;7:98-9.
5. Singleton JA, Lloyd JC, Mootrey GT, Salive ME, Chen RT, Group VW. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. Vaccine 1999;17:2908-17.
6. DeStefano F, for the Vaccine Safety Datalink Research Group. The Vaccine Safety Datalink project. Pharmacoepidemiology and Drug Safety 2001;10:403-6.
7. Zhou W, Pool V, Iskander JK, English-Billiard R, Ball R, Wise RP, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) - United States, 1991-2001. Morbidity and Mortality Weekly Report. Surveillance Summaries 2003;52:1-24.
8. Scheifele DW, Halperin SA. Immunization Monitoring Program, Active: a model of active surveillance of vaccine safety. Seminars in Pediatric Infectious Diseases 2003;14:213-9.
9. Lawrence G, Menzies R, Burgess M, McIntyre P, Wood N, Boyd I, et al. Surveillance of adverse events following immunisation: Australia, 2000-2002. Communicable Disease Intelligence 2003;27:307-23.
10. Duclos P, Delo A, Aguado T, Bilous J, Birmingham M, Kieny MP, et al. Immunization safety priority project at the World Health Organization. Seminars in Pediatric Infectious Diseases 2003;14:233-9.
11. Mehta U, Milstien JB, Duclos P, Folb PI. Developing a national system for dealing with adverse events following immunization. Bulletin of the World Health Organization 2000;78:170-7.
12. Vermeer-de Bondt PE, Labadie J, Rümke HC. Rate of recurrent collapse after vaccination with whole cell pertussis vaccine: follow up study. BMJ 1998;316:902-3.
13. Plesner AM, Hansen FJ, Taudorf K, Nielsen LH, Larsen CB, Pedersen E. Gait disturbance interpreted as cerebellar ataxia after MMR vaccination at 15 months of age: a follow-up study. Acta Paediatrica 2000;89:58-63.
14. Farrington P, Pugh S, Colville A, Flower A, Nash J, Morgan-Capner P, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995;345:567-9.
15. Miller E, Waight P, Farrington P. Safety assessment post-licensure. Developments in Biological Standardization 1998;95:235-43.
16. Ellenberg SS. Safety considerations for new vaccine development. Pharmacoepidemiology and Drug Safety 2001;10:411-5.
17. Ellenberg SS, Chen RT. The complicated task of monitoring vaccine safety. Public Health Reports 1997;112:10-20.
18. Murphy TV, Gargiullo PM, Massoudi MS, Nelson DB, Jumaan AO, Okoro CA, et al. Intussusception among infants given an oral rotavirus vaccine. New England Journal of Medicine 2001;344:564-72.
19. Niu MT, Erwin DE, Braun MM. Data mining in the US Vaccine Adverse Event Reporting System (VAERS): early detection of intussusception and other events after rotavirus vaccination. Vaccine 2001;19:4627-34.
20. Bate A, Lindquist M, Orre R, Edwards IR, Meyboom RH. Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs. European Journal of Clinical Pharmacology 2002;58:483-90.
21. Collet JP, MacDonald N, Cashman N, Pless R. Monitoring signals for vaccine safety: the assessment of individual adverse event reports by an expert advisory committee. Advisory Committee on Causality Assessment. Bulletin of the World Health Organization 2000;78:178-85.
22. Stahl M, Edwards IR, Bowring G, Kiuru A, Lindquist M. Assessing the impact of drug safety signals from the WHO database presented in 'SIGNAL': results from a questionnaire of National Pharmacovigilance Centres. Drug Safety 2003;26:721-7.
23. Fletcher MA, Tetelboum R, Fritzell B. Time to recommend pneumococcal vaccination for all children in Europe: experience in France. European Journal of Pediatics 2002;161 Suppl 2:5132-4.
24. Salmaso S. Inventory of the means of controlling communicable diseases In the European Union, Norway and Switzerland: report on the analysis of the information collected. European Commission, Directorate General V. Rome: Istituto Superiore di Sanita; 1998.
25. Walker E, Raeside F, Dougan D, Lichtenberger J-M, Rey M. Scientific analysis of risks relating to communicable diseases linked to tourism and travel. Edinburgh: Scottish Centre for Infection and Environmental Health (United Kingdom) & Société de Médecine des Voyages (France); 2000.
26. Lankinen KS, editor. Scientific and technical evaluation of vaccination programmes in the European Union. EUVAX Project Report. Helsinki: PSR Consulting Ltd; 2001.
27. Scholtz M, Duclos P. Immunization safety: a global priority. Bulletin of the World Health Organization 2000;78:53-4.
28. Anonymous. Safety monitoring of medicinal products. Uppsala: Uppsala Monitoring Centre; 2000.
29. Kohl KS, Bonhoeffer J, Chen R, Duclos P, Heijbel H, Heininger U, et al. The Brighton Collaboration: enhancing comparability of vaccine safety data. Pharmacoepidemiology and Drug Safety 2003;12:335-40.
30. Bonhoeffer J, Kohl K, Chen R, Duclos P, Heijbel H, Heininger U, et al. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 2002;21:298-302.
31. Wattigney WA, Mootrey GT, Braun MM, Chen RT. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Pediatrics 2001;107:E83.
32. Chen RT, DeStefano F, Davis RL, Jackson LA, Thompson RS, Mullooly JP, et al. The Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA. Bulletin of the World Health Organization 2000;78:186-94.